<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Immunocompromised patients are at risk for invasive molds and resistant <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal infections</z:e> for which <z:chebi fb="1" ids="2682">amphotericin B</z:chebi> may be the only feasible treatment </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0009806'>Nephrogenic diabetes insipidus</z:hpo> (DI) and <z:hpo ids='HP_0001947'>renal tubular acidosis</z:hpo> are known adverse effects of conventional <z:chebi fb="1" ids="2682">amphotericin B</z:chebi>; however, nephrogenic DI has been uncommonly associated with <z:chebi fb="0" ids="2682">liposomal amphotericin B</z:chebi> formulations </plain></SENT>
<SENT sid="2" pm="."><plain>We describe an 18-year-old woman with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> who developed invasive <z:e sem="disease" ids="C0004030" disease_type="Disease or Syndrome" abbrv="">aspergillosis</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>She began treatment with high-dose (10 mg/kg/day) <z:chebi fb="0" ids="2682">liposomal amphotericin B</z:chebi> at home; however, her condition worsened, and she was hospitalized </plain></SENT>
<SENT sid="4" pm="."><plain>Therapy with <z:chebi fb="0" ids="2682">liposomal amphotericin B</z:chebi> was continued until the patient began having symptoms consistent with nephrogenic DI </plain></SENT>
<SENT sid="5" pm="."><plain>These symptoms resolved after discontinuation of <z:chebi fb="0" ids="2682">liposomal amphotericin B</z:chebi>; however, after rechallenge with <z:chebi fb="23" ids="18059">lipid</z:chebi> complex <z:chebi fb="1" ids="2682">amphotericin B</z:chebi> (5 mg/kg/day), the symptoms returned </plain></SENT>
<SENT sid="6" pm="."><plain>The patient's nephrogenic DI was successfully treated with <z:chebi fb="40" ids="35498">diuretics</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>Use of the Naranjo adverse drug reaction probability scale score indicated a probable relationship between <z:chebi fb="0" ids="2682">liposomal amphotericin B</z:chebi> and the development of nephrogenic DI </plain></SENT>
<SENT sid="8" pm="."><plain>To our knowledge, this is the third report of nephrogenic DI induced by <z:chebi fb="0" ids="2682">liposomal amphotericin B</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>This adverse effect is one of many severe adverse effects caused by <z:hpo ids='HP_0000001'>all</z:hpo> formulations of <z:chebi fb="1" ids="2682">amphotericin B</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>A clear understanding of these adverse effects is vital for the clinician to successfully weigh the risks and benefits of antifungal therapy </plain></SENT>
</text></document>